Diabetes Type 2

 
Dementia Risk May be Driven by Multimorbidity vs Single Risk Factors, Suggests a New Study
September 28, 2022

Multimorbidity was associated with a 63% increased risk for dementia among adults older than age 60 years followed for up to 15 years.

ADA, EASD Release Update on Management of Hyperglycemia in Type 2 Diabetes
September 23, 2022

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

T2D Patient Preference Survey Finds Low Side Effect Profile Outranks CVD Protection for Newer OADs
September 23, 2022

New survey findings suggest the need for more in-depth conversations with patients about benefits and harms of newer oral therapies for type 2 diabetes.

FreeStyle Libre 3 CGM Linked with Reduced Hospital Admissions in Patients with T2D
September 22, 2022

Hospital admissions among patients with T2D taking basal insulin only were reduced by 67% one year after beginning treatment with the CGM system.

Semaglutide 2.4 mg: Weight Loss in Real-world Study Matches STEP Trial Program Findings
September 20, 2022

Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.

Tirzepatide Reduces Time to HbA1c Targets by Up to 3 Months vs Semaglutide, Insulin Degludec
September 15, 2022

Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.

Nocturnal Hypertension: 8 Essential Questions
September 14, 2022

Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.

Finerenone: FDA Expands Label to Include Cardiovascular Outcomes Trial Data
September 14, 2022

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

Early-onset Type 2 Diabetes Linked to Significantly Increased Risk for CVD in Later Life: Study
September 13, 2022

A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.

Specific Blood Pressure Thresholds Not Needed When Selecting Patients with T2D for Antihypertensive Treatment, Suggests New Research
August 30, 2022

Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.